10-K: Vir Bio Forges Key Oncology, HDV Partnerships; Reports 2025 Financials

Vir Biotechnology strengthens its pipeline with a global strategic collaboration for prostate cancer candidate VIR-5500 and an exclusive commercial license for its chronic hepatitis delta treatment in Europe, Australia, and New Zealand, while reporting a net loss of $438.0 million for 2025.

Summary

• Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer, leveraging its dAIsY (AI/ML) and PRO-XTEN masking technology platforms.
• The registrational ECLIPSE clinical program for the tobevibart and elebsiran combination in chronic hepatitis delta (CHD) is ongoing, with ECLIPSE 1 and 3 completing enrollment ahead of expectations.
• Topline results for ECLIPSE 1 are expected in Q4 2026, and for ECLIPSE 2 and 3 in Q1 2027.
• Phase 2 SOLSTICE data for the CHD combination showed 77% (24/31) of participants achieved undetectable HDV RNA TND at Week 72, increasing to 88% (21/24) at Week 96 in the evaluable subset, with approximately 90% achieving HBsAg reduction.
• The CHD combination therapy has received FDA Breakthrough Therapy and Fast Track designations, and EMA PRIME and orphan drug designations.
• A global strategic collaboration with Astellas for the co-development and co-commercialization of VIR-5500 (PSMA-targeted TCE for prostate cancer) was executed on February 19, 2026, bringing $335 million in upfront and near-term milestone payments.
• Positive updated Phase 1 monotherapy data for VIR-5500 in metastatic castration-resistant prostate cancer (mCRPC) showed dose-dependent anti-tumor activity (82% PSA50, 53% PSA90 declines in highest dose cohorts) and a favorable safety profile.
• An exclusive commercial license agreement with Norgine Pharma UK Limited for the tobevibart and elebsiran combination in Europe, Australia, and New Zealand was signed on December 15, 2025, including an initial EUR 55 million ($64.3 million) reimbursement and potential for up to EUR 495 million in milestones and royalties.
• Norgine will contribute approximately 25% of go-forward external costs for the ECLIPSE registrational program.
• Phase 1 dose-escalation for VIR-5818 (HER2-targeting TCE) in combination with pembrolizumab continues, with early data showing 50% tumor shrinkage in HER2-positive solid tumors and confirmed partial responses in HER2-positive colorectal cancer.
• The Phase 1 study of VIR-5525 (EGFR-targeting TCE) continues enrollment, with the first patient dosed in July 2025.
• The company decided not to pursue Phase 3 development of the tobevibart and elebsiran combination for chronic hepatitis B (CHB) following Phase 2 results showing 17-21% undetectable HBsAg.
• The FDA revoked the Emergency Use Authorization (EUA) for sotrovimab in December 2024, leading to an expectation of nominal or negative future license and collaboration revenue from the GSK agreement.
• Net loss for the year ended December 31, 2025, was $438.0 million, compared to $522.0 million in 2024, with an accumulated deficit of $1.2 billion.
• Cash, cash equivalents, and investments totaled $781.6 million as of December 31, 2025, expected to fund operations for at least the next 12 months, with the Astellas collaboration extending this into Q4 2027.
• Restructuring initiatives from 2023 and 2024, including R&D facility closures and workforce reductions, were substantially completed by the end of 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report. While the company continues to incur net losses, the strong clinical data for its HDV program and the significant strategic collaborations with Astellas and Norgine provide substantial non-dilutive funding and validate its oncology and infectious disease platforms, extending its cash runway and de-risking development. The termination of less promising programs also indicates strategic focus.

Positives

• ECLIPSE 1 and 3 CHD trials completed enrollment ahead of the company's expectations, indicating efficient clinical progress.
• Phase 2 SOLSTICE data for tobevibart and elebsiran in CHD demonstrated robust efficacy, with 77% (24/31) achieving undetectable HDV RNA TND at Week 72, increasing to 88% (21/24) at Week 96 in the evaluable subset, and approximately 90% HBsAg reduction.
• The CHD combination therapy received FDA Breakthrough Therapy and Fast Track designations, and EMA PRIME and European orphan drug designations, highlighting its potential to address a significant unmet medical need.
• The global strategic collaboration with Astellas for VIR-5500 (prostate cancer) provides $335 million in upfront and near-term payments ($240 million cash, $75 million equity investment at a 50% premium, $20 million manufacturing milestone), significantly bolstering financial resources.
• Positive updated Phase 1 data for VIR-5500 monotherapy in mCRPC showed a favorable safety profile (no dose-limiting toxicities, limited Grade 1 CRS) and dose-dependent anti-tumor activity (82% PSA50, 53% PSA90 declines, 45% objective responses in RECIST-evaluable patients).
• The exclusive commercial license agreement with Norgine for the CHD treatment in Europe, Australia, and New Zealand includes an initial EUR 55 million ($64.3 million) reimbursement and potential for up to EUR 495 million in future milestones and tiered royalties.
• Norgine's contribution of approximately 25% of go-forward external ECLIPSE program costs reduces the company's financial burden for this registrational program.
• Early Phase 1 efficacy data for VIR-5818 (HER2-positive solid tumors) showed 50% tumor shrinkage and confirmed partial responses in HER2-positive colorectal cancer, an area traditionally unresponsive to immunotherapies.
• Cash, cash equivalents, and investments of $781.6 million as of December 31, 2025, are expected to fund operations for at least the next 12 months, with the Astellas collaboration extending this into Q4 2027.
• Net loss decreased from $522.0 million in 2024 to $438.0 million in 2025, partly due to cost savings from restructuring initiatives.

Negatives

• Incurred a net loss of $438.0 million for the year ended December 31, 2025, and an accumulated deficit of $1.2 billion, indicating continued unprofitability.
• The company decided not to pursue Phase 3 development of the tobevibart and elebsiran combination in chronic hepatitis B (CHB) due to less compelling Phase 2 results, representing a pipeline discontinuation.
• The FDA revoked the Emergency Use Authorization (EUA) for sotrovimab in December 2024, leading to an expectation of nominal or negative future license and collaboration revenue from the GSK agreement.
• Grant revenue significantly decreased from $10.493 million in 2024 to $2.036 million in 2025, primarily due to the termination of the BARDA agreement and expiration of Gates Foundation grants.
• Interest income decreased from $71.809 million in 2024 to $40.238 million in 2025, reflecting lower cash balances and interest rates.
• The company expects to continue incurring significant expenses and net losses in the foreseeable future.
• Workforce reductions of approximately 75 net positions in 2023 and 140 employees in 2024 were implemented as part of restructuring initiatives.

Risks

• The company has incurred net losses and anticipates continuing to incur net losses in the foreseeable future.
• Substantial additional funding is required to finance operations, and an inability to raise capital could force delays, reductions, or termination of R&D programs.
• Future success is substantially dependent on the successful clinical development, regulatory approval, and commercialization of product candidates in a timely manner.
• The development of additional product candidates is risky and uncertain, with no assurances of success or ability to replicate the approach for other diseases.
• Developing product candidates in combination with other therapies exposes the company to additional risks, including potential toxicities or revocation of approval for combination components.
• Success in preclinical or early-stage clinical studies may not be indicative of results in future clinical studies, and substantial financial resources committed may not be recouped.
• Interim, top-line, and preliminary data from clinical studies may change as more patient data become available and are subject to audit and verification procedures.
• Fast Track, Breakthrough Therapy, PRIME, and orphan drug designations do not guarantee faster regulatory approval or approval at all, and can be withdrawn.
• Clinical product development involves a lengthy and expensive process, with potential for additional costs, substantial delays, or difficulties in clinical studies.
• Enrollment and retention of patients in clinical studies is an expensive and time-consuming process and could be delayed or made impossible by factors outside the company's control, including geopolitical events or pandemics.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or limit commercial potential.
• The company is party to strategic collaboration and license agreements requiring substantial payments upon achievement of milestone events and, in certain cases, has relinquished important rights.
• The deployment of AI in discovery, development, and engineering efforts could lead to flawed, biased, or inaccurate results, or expose the company to competitive and reputational harm.
• Product candidates, if approved, may fail to achieve adoption by physicians, patients, third-party payors, or clinical guidelines necessary for commercial success.
• Reliance on third parties to produce clinical and future commercial supplies of product candidates could lead to delays or supply shortages.
• Reliance on third parties to conduct, supervise, and monitor preclinical and clinical studies; unsatisfactory performance by these third parties may harm the business.
• Breach of license agreements could result in the loss of the ability to continue development and commercialization of related product candidates.
• Inability to obtain and maintain patent protection for product candidates and technology, or if the scope of protection is not sufficiently broad, could adversely affect commercialization.
• High dependence on key personnel; inability to retain or recruit management, clinical, and scientific personnel could harm the business.
• Challenges in managing growth could delay business plans or disrupt operations.
• Information system failures or security breaches could disrupt product development, business operations, or lead to unauthorized access or disclosure of personal information.
• The market price of common stock has been, and may in the future be, volatile and fluctuate substantially.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization.
• Product candidates, if approved, may face competition sooner than anticipated from biosimilar or generic products.
• Relationships with customers, physicians, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare regulations.
• Coverage and adequate reimbursement may not be available for commercialized product candidates, making profitable sales difficult.
• Healthcare legislative, administrative, and other reform measures (e.g., Inflation Reduction Act of 2022) may negatively impact the business.
• Subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, with non-compliance leading to criminal/civil liability.
• The ability to use net operating losses (NOLs) to offset future taxable income may be subject to certain limitations.
• The potential exercise by the Gates Foundation of its licenses to certain intellectual property could have an adverse impact on the company's market position.
• Trademarks may be infringed or successfully challenged, resulting in harm to the business.

Future Outlook

The company expects to continue incurring significant expenses and net losses in the foreseeable future as it advances its product candidates through preclinical and clinical development and seeks regulatory approval. Current cash, cash equivalents, and investments are projected to fund operations for at least the next 12 months, with the Astellas collaboration extending this runway into the fourth quarter of 2027. Key clinical data readouts include topline results from ECLIPSE 1 in Q4 2026, and ECLIPSE 2 and 3 in Q1 2027. The company anticipates initiating dose-expansion cohorts for VIR-5500 in Q2 2026, followed by pivotal Phase 3 trials in 2027, and expects response data for VIR-5818 in H2 2026. Nominal or negative license and collaboration revenue is expected from the GSK agreement going forward.

Management Comments

• Marianne De Backer, CEO, stated: 'We believe Norgine has the ideal expertise and reach in key international markets to maximize the impact of our investigational treatment for CHD. This agreement advances our commitment to sustainably develop and commercialize the tobevibart and elebsiran combination treatment globally while advancing our innovative clinical pipeline.'
• Marianne De Backer, CEO, also commented: 'Norgine's proven track record in specialty medicines across Europe, Australia and New Zealand complements our clinical development mettle and ongoing registrational efforts. Together, we aim to broaden access and improve outcomes for people living with this severe disease.'

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is characterized by rapidly advancing technologies and intense competition. Vir Bio's strategy of leveraging AI/ML (dAIsY) and PRO-XTEN masking platforms positions it in cutting-edge areas of drug discovery. The company's strategic focus on high-unmet-need indications like chronic hepatitis delta (HDV) and oncology (T-cell engagers) aligns with broader industry trends towards specialized therapies with potentially higher commercial value. The recent collaborations with Astellas and Norgine are strategic moves to de-risk development costs and leverage established commercial infrastructures in specific territories, a common practice for clinical-stage biotechs. The termination of the chronic hepatitis B (CHB) program and the opt-out of the RSV program highlight the high-risk nature of drug development and the necessity for companies to prioritize pipeline assets based on evolving clinical data and market potential.

Comparison to Industry Standards

• **HDV Treatment (Tobevibart + Elebsiran):** The combination therapy's Phase 2 SOLSTICE data, showing 88% HDV RNA TND at Week 96 in evaluable patients, is highly promising. This compares favorably to Gilead's bulevirtide, an EMA-approved treatment expected for US launch in H1 2026, which has shown limited HDV clearance and requires daily injections. Vir Bio's combination, with its strong efficacy and favorable safety profile, has the potential to be a new standard of care, supported by FDA Breakthrough Therapy and EMA PRIME designations. Mirum's brelovitug is also in pivotal trials, indicating a competitive landscape for this severe disease.
• **Prostate Cancer (VIR-5500):** Phase 1 data for VIR-5500 in mCRPC, demonstrating 82% PSA50 and 53% PSA90 declines, and 45% objective responses in heavily pretreated patients, represents a strong signal. Novartis's lutetium Lu 177 vipivotide tetraxetan is the only currently approved PSMA-targeted therapy. Other companies like Janux (JANX007 TCE), Johnson & Johnson (JNJ-8177 ADC), Regeneron, GSK, and Bayer are also developing PSMA therapies. VIR-5500's dual-masked T-cell engager approach aims to improve safety and therapeutic index, potentially offering a differentiated profile in a competitive, high-value market.
• **HER2-Expressing Solid Tumors (VIR-5818):** Early Phase 1 data showing 50% tumor shrinkage and confirmed partial responses in HER2-positive colorectal cancer (CRC), a tumor type traditionally unresponsive to immunotherapies, is a notable achievement. Approved HER2 therapies include ADCs (AstraZeneca/Daiichi Sankyo's trastuzumab deruxtecan, Roche's trastuzumab emtansine), monoclonal antibodies (Roche's trastuzumab & pertuzumab), and inhibitors (Pfizer's tucatinib). VIR-5818's dual-masked TCE mechanism is designed to mitigate on-target, off-tumor toxicity, potentially offering a wider therapeutic window compared to existing HER2-targeted agents.
• **EGFR-Expressing Solid Tumors (VIR-5525):** This program is in early Phase 1 development. Current EGFR-targeting monoclonal antibodies like Lilly's cetuximab and Amgen's cetuximab are approved for colorectal cancer. Similar to other PRO-XTEN TCEs, VIR-5525 aims to leverage masking technology to enhance tumor specificity and safety, addressing limitations of conventional EGFR therapies and potentially competing with other developers like Janux, Regeneron, and J&J.

Corporate Governance

Legal Proceedings

• The company is not currently party to any material legal proceedings and is unaware of any pending or threatened legal proceedings that could have an adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• **Gates Foundation:** Purchased $40.0 million of common stock in January 2022. The company is obligated to use proceeds for charitable purposes related to its vaccinal antibody program and adhere to global access commitments. The Gates Foundation retains potential non-exclusive license rights if obligations are not met.
• **GSK:** Collaboration agreements (2020 & 2021) for SARS-CoV-2 and RSV programs. The 2020 agreement involved profit-sharing for sotrovimab (now revoked EUA), and the 2021 agreement led to the company opting out of the RSV program with low single-digit royalties on net sales if commercialized.
• **Brii Biosciences Limited:** Collaboration, option, and license agreement for elebsiran and tobevibart in the Greater China Territory. Brii Bio exercised options for both compounds, paying option exercise fees and potentially future milestones and royalties. The company holds Class A ordinary shares in Brii Bio Parent.
• **Alnylam Pharmaceuticals, Inc.:** Collaboration and license agreement for siRNA product candidates, including elebsiran. The Restated Alnylam Agreement in March 2025 involved a $30.0 million payment to Alnylam and potential future development, regulatory, and sales milestones, plus tiered royalties.
• **Sanofi (Amunix Pharmaceuticals Inc.):** License agreement for the PRO-XTEN universal masking technology and three clinical-stage masked T-cell engagers. The company made an upfront payment of $100.0 million and a $75.0 million milestone payment upon VIR-5525 achieving first-in-human dosing. The company will share 20% of certain future collaboration proceeds from the Astellas agreement with Sanofi.
• **Astellas US LLC:** Global strategic collaboration for VIR-5500, including a $75 million equity investment in the company's common stock at a 50% premium.

Stakeholder Impact

• **Shareholders:** Potential for long-term value creation from successful pipeline development and strategic collaborations, but also faces dilution risk from future equity raises and stock price volatility inherent in the biopharmaceutical sector.
• **Patients (Chronic Hepatitis Delta):** The tobevibart and elebsiran combination offers a promising new treatment option for a high unmet medical need, potentially improving patient outcomes.
• **Patients (Oncology):** The masked T-cell engager programs (VIR-5500, VIR-5818, VIR-5525) offer potential novel, safer, and more effective therapies for various solid tumors, including mCRPC and HER2/EGFR-expressing cancers.
• **Employees:** The company underwent workforce reductions in 2023 and 2024 as part of restructuring initiatives, impacting approximately 75 and 140 employees, respectively. Ongoing human capital programs focus on engagement, innovation, and development.
• **Collaborators (Astellas, Norgine, GSK, Brii Bio, Alnylam, Sanofi, Gates Foundation):** Strengthened partnerships, shared development costs, and expanded commercial reach, fostering mutual benefits and leveraging complementary expertise.
• **Suppliers/CDMOs:** Continued reliance on third-party contract development and manufacturing organizations for product candidates, indicating ongoing business for these partners but also exposing the company to supply chain risks.

Next Steps

• Topline results from the ECLIPSE 1 clinical trial are expected in Q4 2026.
• Topline results from the ECLIPSE 2 and ECLIPSE 3 clinical trials are expected in Q1 2027.
• Initiate monotherapy dose-expansion cohorts for VIR-5500 in late-line mCRPC in Q2 2026.
• Initiate combination dose-expansion cohorts for VIR-5500 in early-line mCRPC and metastatic hormone-sensitive prostate cancer (mHSPC) in Q2 2026.
• Pivotal Phase 3 trials for VIR-5500 are anticipated in 2027.
• Response data for VIR-5818 in combination with pembrolizumab is expected in H2 2026.
• Finalize a commercial supply agreement and relevant terms for tobevibart and elebsiran by the end of 2026.
• Continue advancing multiple undisclosed PRO-XTEN dual-masked TCEs in preclinical studies.
• Continue developing HIV broadly neutralizing antibodies (bnAbs) with Gates Foundation support.
• Complete manufacturing technology transfer for the Astellas collaboration, anticipated in Q2 or Q3 2027.

Key Dates

Recommendation

The company demonstrates strong scientific capabilities and strategic execution through its recent collaborations and positive early-stage clinical data in high-unmet-need areas like HDV and prostate cancer. The Astellas and Norgine deals provide significant funding and commercial pathways, extending the cash runway and validating its oncology and infectious disease platforms. However, the company remains in a clinical stage with substantial ongoing net losses and faces inherent risks of drug development, including potential clinical trial failures, regulatory hurdles, and intense competition. The decision to halt the CHB program highlights the high-risk nature of the industry. A 'Hold' recommendation reflects the promising pipeline and strategic partnerships, balanced against the significant execution risks and continued unprofitability typical of a clinical-stage biopharmaceutical company.

Keywords

Biotechnology, Biopharmaceutical, Infectious Diseases, Cancer, Hepatitis Delta Virus (HDV), Prostate Cancer, T-cell Engagers (TCEs), VIR-5500, Tobevibart, Elebsiran, PRO-XTEN, Clinical Trials, Regulatory Approval, Collaborations, Drug Development, Oncology, Immunology, AI/Machine Learning, Orphan Drug, Breakthrough Therapy, Fast Track, EMA PRIME, HER2-expressing tumors, EGFR-expressing tumors, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chronic Hepatitis B (CHB), HIV broadly neutralizing antibodies (bnAbs), Intellectual Property, SEC Filing, 10-K